Teva Pharmaceuticals

Company Overview

Snapshot

Founded in January 1901, Teva Pharmaceuticals operates with over 29,000 employees and has raised over $900 million across five funding rounds. The company went public on the TASE in January 1951 and on the NYSE in January 1982. In April 2026, Teva Pharmaceuticals acquired Emalex Biosciences.

Business overview

Teva Pharmaceuticals is a global pharmaceutical company specializing in the development, production, and marketing of generic drugs, specialty pharmaceuticals, and active pharmaceutical ingredients. Headquartered in Israel, the company's extensive product portfolio includes over 3,600 medicines, serving markets worldwide with approximately 120 billion tablets and capsules produced annually across 70 manufacturing facilities. Teva operates within the Health Tech & Life Sciences sector, with a focus on Pharma & Medical Biotechnology and Drugs Discovery & Development, targeting healthcare and life sciences customers.

Strategic signal

In September 2025, Teva’s Emrusolmin was granted U.S. FDA Fast Track Designation for the treatment of Multiple System Atrophy. This designation indicates the FDA's recognition of the drug's potential to address an unmet medical need for a serious condition, signaling a significant regulatory and clinical validation for Teva's specialty pipeline and potentially accelerating its path to market.

Company Intelligence Q&A

What was a significant recent regulatory milestone for Teva Pharmaceuticals?

In September 2025, Teva’s Emrusolmin received U.S. FDA Fast Track Designation for the treatment of Multiple System Atrophy, highlighting its potential to address an unmet medical need.

What was Teva Pharmaceuticals' most recent acquisition?

In April 2026, Teva Pharmaceuticals acquired Emalex Biosciences, further expanding its portfolio.

When did Teva Pharmaceuticals go public on the NYSE?

Teva Pharmaceuticals went public on the NYSE in January 1982.

What was a notable funding event for Teva Pharmaceuticals in March 2026?

In March 2026, Teva Pharmaceuticals secured a PIPE funding round from Blackstone.

What was a key development regarding Teva's product portfolio in September 2025?

In September 2025, Teva and Medincell’s Risperidone LAI was approved in Canada as LONGAVO®, expanding treatment options for patients.